Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland

2018 ◽  
Vol 21 (4) ◽  
pp. 374-381 ◽  
Author(s):  
Bernd Brüggenjürgen ◽  
Thomas Reinhold
Keyword(s):  
Cost Effectiveness ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Symptomatic Treatment ◽  
Subcutaneous Immunotherapy

Efficacy of sublingual immunotherapy tablets in dust mite and pollen allergy

2021 ◽  
Vol 42 (1) ◽  
pp. 36-42 ◽  
Author(s):  
Yuriy Bisyuk ◽  
Ilona DuBuske ◽  
Lawrence M. DuBuske
Keyword(s):  
T Cells ◽  
Comparative Analysis ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Pollen Allergy ◽  
Subcutaneous Immunotherapy ◽  
Efficacy And Safety ◽  
Dust Mite ◽  
Timothy Grass Pollen ◽  
New Biomarkers

The latest evidence on the mechanisms, efficacy, and safety of sublingual immunotherapy (SLIT) was reviewed. Interleukin (IL) 35 and IL-35‐producing regulatory T cells were assessed as new biomarkers for SLIT responsiveness. A detailed analysis of clinical studies, including timothy grass pollen, 5-grass pollen, ragweed, and house-dust mite SLIT tablets, was provided, including a comparative analysis of efficacy and safety of SLIT versus subcutaneous immunotherapy.

Safety of sublingual grass pollen immunotherapy after anaphylaxis

2008 ◽  
Vol 123 (6) ◽  
pp. 683-684 ◽  
Author(s):  
J R Nichani ◽  
J de Carpentier
Keyword(s):  
Case Report ◽  
Adverse Events ◽  
Grass Pollen ◽  
Side Effect ◽  
Sublingual Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Side Effect Profile ◽  
Fatal Complication ◽  
Discontinuation Of Treatment ◽  
Safe Treatment Option

AbstractAim:To demonstrate that sublingual immunotherapy is a safe treatment option in patients who have previously suffered anaphylaxis when undergoing subcutaneous grass pollen immunotherapy.Case report:We report two patients who developed a systemic anaphylactic reaction following subcutaneous grass pollen immunotherapy, resulting in discontinuation of treatment. Following treatment of the acute anaphylactic episode, both patients were subsequently safely commenced on sublingual grass pollen immunotherapy.Conclusion:Injection immunotherapy has a relatively low risk of severe adverse events, although anaphylaxis is a potentially fatal complication and usually results in termination of the immunotherapy programme. Sublingual immunotherapy has a safer side effect profile than subcutaneous immunotherapy, with no reported cases of anaphylaxis.

scholarly journals Real world effectiveness and cost consequences of grass pollen SCIT compared with SLIT and symptomatic treatment

2021 ◽  
Author(s):  
Bernd Brüggenjürgen ◽  
Ludger Klimek ◽  
Thomas Reinhold
Keyword(s):  
Allergic Rhinitis ◽  
Cost Effectiveness ◽  
Real World ◽  
Grass Pollen ◽  
Cost Effective ◽  
Symptomatic Treatment ◽  
Economic Modelling ◽  
Allergen Specific Immunotherapy ◽  
Life Years ◽  
Adherence Data

Abstract Purpose Real-world evidence (RWE) with regard to allergen-specific immunotherapy (AIT) adherence is increasingly available. Economic modelling has already shown AIT to be cost-effective in the treatment of allergic rhinitis compared with symptomatic treatment. However, analyzing sublingual (SLIT) and subcutaneous (SCIT) immunotherapeutic approaches based on RWE adherence data are not available for Germany. This analysis outlines the cost-effectiveness of SCIT compared with SLIT as well as a symptomatic treatment modality on the basis of recent RWE adherence data. Methods A Markov model, with predefined disease stages and a time period of 9 years, was adapted for this analysis. A 6-grass subcutaneous allergoid SCIT preparation and a 5-grass pollen SLIT tablet was employed as AIT administrations. Quality-adjusted life years (QALYs) were calculated based on symptom scores and used as the effectiveness variable. Total costs and cost effectiveness of SCIT, SLIT and symptomatic treatment (ST) were calculated. Model uncertainties were estimated by means of additional sensitivity analyses. Applied discount rate was 3%. Results Both SCIT and SLIT preparations proved superior compared to symptomatic treatment with regard to effectiveness. Although more expensive, AIT also proved to be cost-effective. A direct comparison of SCIT (Allergovit®) and SLIT (Oralair®) showed lower total costs for SCIT treatment over the study period of 9 years (SCIT 1779 € versus SLIT 2438 €) and improved effectiveness (SCIT 7.17 QALYs versus SLIT 7.11 QALYs). Conclusion AIT represents a cost-effective treatment option for patients with allergic rhinitis compared with symptomatic treatment. SCIT appeared to be dominant and cost-effective, due in particular to higher patient adherence and lower drug costs.

scholarly journals Plant Food Allergy Improvement after Grass Pollen Sublingual Immunotherapy: A Case Series

Pathogens ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1412
Author(s):  
Fabiana Furci ◽  
Luisa Ricciardi
Keyword(s):  
Food Allergy ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Case Series ◽  
Food Allergies ◽  
Subcutaneous Immunotherapy ◽  
Pollen Extract ◽  
Plant Food ◽  
Good Tolerance ◽  
Sublingual Tablet

Background: Cross-reactivity between pollens and plant food has been widely described. Pollen extract subcutaneous immunotherapy in patients with pollens and plant food allergy has been shown to improve tolerance not only to inhalant allergens but also to reduce symptoms in patients with various food allergies. Methods: We retrospectively report our experience with 15 female patients with a positive history for moderate, persistent allergic rhinitis due to grass pollen and oropharyngeal symptoms after ingestion of different plant food. These patients followed a five-grass pollen sublingual tablet immunotherapy for three years in a discontinuous pre-co-seasonal scheme. Results: All 15 patients treated with the 5-grass pollen sublingual tablet immunotherapy, taken once daily for 3 years on a 7-month course, showed improved ocular/nasal symptoms, with a reduction in the use of symptomatic drugs (e.g., nasal corticosteroids and H1 antihistamines). After the first seven-month course of immunotherapy, all patients declared a good tolerance to the intake of fruits and vegetables, and in particular, good tolerance to the offending foods. Conclusions: In conclusion, we have observed improvement of both respiratory and plant food allergies after sublingual immunotherapy (SLIT) with a five-grass pollen tablet.

Sign in / Sign up

Export Citation Format

Share Document